An Immunotherapy Company Worth Understanding
Every few years, a company emerges in the biotech space that challenges the fundamental assumptions of how we treat disease. ImmunityBio, Inc. (NASDAQ: IBRX) appears to be making a serious case for being one of those companies — not through hype, but through a rapid succession of regulatory approvals, compelling clinical data, and a platform science approach that is drawing attention from healthcare systems on four continents.
As a healthcare marketing agency that works exclusively with medical practices, behavioral health organizations, and healthcare providers, we track emerging therapies and industry shifts that affect how providers communicate with patients, how practices position themselves, and where the broader landscape of patient care is heading. What's happening at ImmunityBio — particularly across its last ten press releases from January through February 2026 — is worth paying close attention to, whether you're a clinician, a practice administrator, or simply a healthcare professional who wants to understand where immunotherapy is going.
This is not a company producing a single drug for a single disease. ImmunityBio is building what increasingly looks like an immune restoration operating system — a layered technology platform with its foundational therapy, Anktiva, now approved across 33 countries in four regulatory jurisdictions, with clinical programs active in bladder cancer, lung cancer, glioblastoma, lymphoma, ovarian cancer, and cancer vaccine prevention trials. The speed at which this has happened is, by any objective measure, extraordinary.
The Foundation: What Is Anktiva and Why Does It Matter?
At the center of ImmunityBio's platform is Anktiva (nogapendekin alfa inbakicept-pmln), a first-in-class IL-15 receptor superagonist. In practical terms, Anktiva instructs the body to produce more natural killer (NK) cells and T cells — the immune system's primary tools for identifying and destroying threats, from cancer cells to viral pathogens. The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of these key immune cells. Anktiva is an IgG1 fusion complex consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells.
This is a fundamentally different approach than many existing cancer therapies. Rather than targeting the tumor directly (as chemotherapy does) or removing one of the tumor's defense mechanisms (as checkpoint inhibitors do), Anktiva strengthens the body's own immune army at the root level. By activating NK cells, Anktiva overcomes the tumor escape phase — where cancer cells develop resistance to T cell attack — and restores memory T cell activity, which is critical for long-duration complete responses. When your NK and T cell counts are healthy, your immune system can do what it was designed to do.
The FDA granted Anktiva Breakthrough Therapy designation and approved it in April 2024 for use in combination with BCG (Bacillus Calmette-Guérin) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. It was the first FDA-approved immunotherapy for this specific indication that activates NK cells, T cells, and memory T cells. Clinical data published in The Journal of Urology in December 2025 showed that Anktiva plus BCG demonstrated a 96% disease-specific survival rate and 83% progression-free survival at 36 months in patients with BCG-unresponsive papillary NMIBC — with a safety profile consistent with BCG treatment alone, showing just 3% grade 3 and no grade 4 or 5 treatment-related adverse events.
But the science behind Anktiva isn't limited to bladder cancer — and that's where the story gets much larger.
The Platform: More Than a Single Drug
What differentiates ImmunityBio from a typical single-asset biotech company is the layered platform architecture built on top of Anktiva's foundation. The company isn't just selling a drug — it's constructing an immune restoration and targeting system that can be adapted across disease types. Founder and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong has described this as a "BioShield" platform — the idea that by restoring immune competence at the systemic level, you create the prerequisite conditions for targeted interventions to work.
The ImmunityBio Platform Architecture
The practical logic of this layered approach: Anktiva builds the immune army. The NK cell therapies provide reinforcements when the patient's own system is too depleted. The engineered cells give the army specialized weapons. And the vaccines give them their specific mission. Each layer addresses different clinical scenarios — and together, they form something closer to an operating system for immune restoration than a standalone treatment.
What makes this particularly compelling is the concept of lymphopenia reversal. Many cancer patients — especially those who have been through radiation and chemotherapy — suffer from severely depleted immune cell counts. This immune collapse isn't just a side effect; it's increasingly understood as a major contributor to treatment failure and poor outcomes. By restoring those counts as the foundational step, Anktiva creates the conditions for subsequent therapies (whether checkpoint inhibitors, CAR-NK cells, or vaccines) to actually work as intended.
Competitive Landscape
Anktiva: The #1-Ranked Immune Agent — Ahead of Keytruda
In the BCG-unresponsive bladder cancer space, Anktiva has emerged as a direct competitor to Merck's blockbuster Keytruda (pembrolizumab) and Ferring Pharmaceuticals' gene therapy Adstiladrin. ImmunityBio founder Dr. Patrick Soon-Shiong has described Anktiva as the "#1 ranked" immune therapy — a reference to its mechanism as an immune system activator (the "gas pedal") versus checkpoint inhibitors like Keytruda, which function by releasing immune "brakes" but don't directly stimulate new immune cell production.
The clinical data in bladder cancer support a meaningful differentiation. In head-to-head comparison of published trial results, Anktiva plus BCG has demonstrated a substantially higher complete response rate than Keytruda, with responses that appear more durable over time. Some patients have remained cancer-free for over 53 months — more than four years — with more than half of responders maintaining responses beyond 45 months.
96% disease-specific survival at 3 yrs
in BCG-unresponsive NMIBC CIS
Pharma data intelligence outlet Evaluate listed Anktiva among the top 10 drug launches of 2024, projecting the immunotherapy could reach nearly $900 million in annual sales by 2028. With the BCG-naïve trial now fully enrolled (366 patients) and showing a statistically significant improvement in duration of complete response versus BCG alone at interim analysis, the addressable market for Anktiva is poised to expand substantially.
10 Press Releases, 8 Weeks: A Timeline of Accelerating Momentum
The pace of ImmunityBio's regulatory and clinical progress in early 2026 has been remarkable. Between January and February 2026, the company issued a series of announcements that collectively paint a picture of a platform expanding across geographies, indications, and clinical programs simultaneously. Here is that timeline:
The Global Commercial Buildout
What has been particularly notable about ImmunityBio's recent execution is the speed and structure of its international commercial infrastructure. In under two years from initial FDA approval, the company has moved from a single-country approval to a coordinated global presence with dedicated subsidiaries and distribution partnerships across three major regions.
United States
FDA-approved since April 2024. Internal commercial team scaling. Expanded Access Program for rBCG active at 57 urology centers with over 500 patients enrolled. J-Code obtained January 2025 for streamlined physician billing. Q4 2025 net product revenue of $38.3 million.
European Union & UK
UK MHRA approved July 2025. European Commission conditional marketing authorization February 2026 covering 30 countries. Accord Healthcare partnership deploying 100+ commercial professionals. Dublin-based subsidiary established. Approximately 157,000 NMIBC diagnoses annually in the EU and UK.
Saudi Arabia & MENA
SFDA dual approvals (bladder + lung cancer) January 2026 — the first global approval for Anktiva in lung cancer. Partnership with Biopharma and Cigalah Healthcare. Wholly owned subsidiary established. Distribution expected within 60 days. Discussions underway for multi-tumor expansion and rBCG submission.
Regulatory Pipeline
Submissions to additional regulatory authorities planned throughout 2026. FDA discussions regarding accelerated approval pathway for NSCLC underway. BCG-naïve BLA filing targeted Q4 2026. U.S. FDA meeting for rBCG scheduled March 2026. Response submitted to FDA regarding papillary-only NMIBC data.
The commercial partnerships themselves are significant and worth understanding in detail.
The Accord Healthcare Agreement: A European Commercialization Engine
On February 19, 2026, ImmunityBio announced a strategic partnership with Accord Healthcare — one of Europe's fastest-growing pharmaceutical companies, recognized for its leadership in biosimilars and specialty oncology medicines, with coverage across more than 85 countries globally. This partnership is designed to serve as the commercial engine for Anktiva's European launch, and its scope is substantial.
Under the agreement, Accord Healthcare will deploy a team of over 100 sales, medical, and marketing professionals dedicated to driving the uptake of Anktiva across Europe, the United Kingdom, and the European Free Trade Association (EFTA) states — covering more than 30 countries in total. The target patient population includes those with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), where approximately 157,000 people are diagnosed annually in the EU and UK alone, with an estimated 10% to 20% presenting with the specific CIS indication that Anktiva is authorized to treat.
The partnership follows directly on the European Commission's conditional marketing authorization of Anktiva in February 2026 for use in combination with BCG — making the timing a coordinated market entry strategy rather than an exploratory licensing deal. To support the infrastructure required for this scale of launch, ImmunityBio established a new wholly owned subsidiary in Dublin, Ireland, which will serve as the hub for distribution, regulatory affairs, and commercialization strategy across the European market.
"Our partnership with ImmunityBio reflects our shared commitment to expanding access to innovative cancer therapies for patients in Europe. ANKTIVA represents an important advancement for eligible patients with BCG-unresponsive NMIBC CIS, and we are pleased to support its introduction across our markets." — Paul Tredwell, Global CEO, Accord Healthcare
The strategic scope of the deal aims to leverage Accord's existing oncology network infrastructure — built over years of European market presence — to accelerate access to Anktiva rather than building a commercial footprint from scratch. For a company like ImmunityBio, which has been primarily U.S.-focused commercially, this is a meaningful de-risking of the international expansion strategy.
The MENA Partnership: Biopharma and Cigalah Healthcare
In the Middle East, Biopharma and Cigalah Healthcare — two of the largest pharmaceutical commercial and distribution companies in the MENA region — will handle commercialization and distribution in Saudi Arabia and beyond. ImmunityBio established a wholly owned subsidiary in the Kingdom of Saudi Arabia, and Anktiva is expected to be available for distribution within 60 days. The Registration Certificate of Pharmaceutical Product with pricing has already been issued by the Saudi FDA. The company has also initiated discussions with the UAE's Emirates Drug Establishment to expand access further across the region.
The MENA region has significant unmet oncology needs. Lung cancer is among the most prevalent cancers in Saudi Arabia, ranking as the third most common cancer among males over 45. Lebanon has the highest incidence of bladder cancer cases globally, with Syria and Egypt also ranking among the countries with the greatest burden of the disease.
The Cancer Vaccine Frontier
Perhaps the most forward-looking component of ImmunityBio's platform is its cancer vaccine program. The company's NANT Cancer Vaccine (NCV) uses a second-generation adenovirus vector to deliver tumor-associated antigens to dendritic cells — a type of immune cell that acts as the body's "intelligence officers," presenting threat information to T cells so they can mount a targeted response.
The approach works like this: an adenovirus carrying specific antigens is administered to the patient. Due to its icosahedral shape (a polyhedron with 20 faces), the adenovirus naturally migrates toward dendritic cells, particularly in the lungs. The dendritic cells internalize the antigens, travel through lymphatic vessels to the nearest lymph node, and present the processed peptides on their MHC molecules to naïve T cells. This interaction, aided by co-stimulatory signals like interferon-gamma, activates the T cells — triggering the production of CD8+ cytotoxic T cells (which directly kill cancerous or infected cells) and CD4+ helper T cells (which coordinate the broader immune response, including B cell activation for antibody production).
The critical connection to the rest of the platform: if a patient doesn't have sufficient T cells, this entire cascade falls apart. Anktiva solves that prerequisite. When combined with Anktiva to ensure adequate NK and T cell counts, the vaccine approach creates a feedback loop — Anktiva supplies the soldiers, and the vaccine gives them their mission.
Lynch Syndrome Cancer Prevention (NCI-Sponsored): The randomized Phase 2 trial has completed enrollment of its first two phases and initiated the randomized controlled portion. This is a landmark study — the first to evaluate adenovirus-delivered vaccines combined with an immune enhancer to target cancer-specific proteins before cancer develops. The NCV is a tri-valent combination of antigens (CEA, MUC1, brachyury) delivered by a second-generation adenovirus vector, studied together with Anktiva. According to the National Cancer Institute, an estimated 5 to 10 percent of cancers are hereditary, making prevention-focused interventions potentially transformative for tens of thousands of patients annually.
Endometrial Cancer (AdHER2DC Vaccine): A Phase 1/2 trial enrolling 60 participants with HER2-positive endometrial cancer, combining the AdHER2DC vaccine (autologous dendritic cells transduced with HER2-expressing adenovirus) with Anktiva, pembrolizumab, and lenvatinib. HER2 is elevated in approximately 30% of endometrial cancers. Completion expected in 2026.
Multi-Tumor Combinations: Additional vaccine studies have explored combinations across pancreatic, breast, colorectal, and head and neck cancers, with the NCV approach demonstrated to induce complete remission across multiple tumor types in patients who previously progressed on standard-of-care therapy.
The Glioblastoma Breakthrough: A Closer Look
Among all of ImmunityBio's clinical programs, the glioblastoma data may be the most striking — in part because glioblastoma (GBM) is one of the most devastating and treatment-resistant cancers in existence. The five-year survival rate for glioblastoma is just 6.8%, according to the National Brain Tumor Society, and the median overall survival for patients with recurrent disease is approximately 6 to 9 months. There has been little meaningful therapeutic progress in this disease for decades.
The QUILT-3.078 study is testing a chemotherapy-free combination of Anktiva, PD-L1-targeted CAR-NK cells (PD-L1 t-haNK), bevacizumab, and tumor treating fields in patients with recurrent GBM. The results reported in January 2026 are generating attention across the oncology community:
Of 23 enrolled patients with recurrent or progressive GBM, 19 remain alive as of January 22, 2026. Median overall survival has not yet been reached — in a population where the historical benchmark is 6–9 months. The longest survival from time of disease recurrence has reached 12 months and is ongoing.
Baseline mean absolute lymphocyte count was 0.9 × 10³/μL (severe lymphopenia). Within one treatment cycle, mean ALC rose to ≥ 1.4 × 10³/μL (p <0.001) — demonstrating statistically significant immune restoration. Immune competence was maintained with significant increases from baseline at all assessments through 20 weeks.
Across all 41 GBM patients treated (23 from the study, 18 from single-patient INDs), only three treatment-related serious adverse events were reported. Zero cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) — complications that have historically limited CAR-T cell therapy.
In the single-patient IND population, seven first-line patients are all alive to date.
"Lymphopenia has been underrecognized as a significant consequence of our standards of care. Approaches that integrate immune-based therapies that maintain immune competence with direct clinical and biological observation are essential if we are to make progress." — Joshua Bernstock, M.D., Ph.D., Clinical Fellow, Harvard Medical School and Neurosurgeon, Brigham and Women's Hospital
The implications here extend beyond glioblastoma. The finding that restoring lymphocyte counts through Anktiva — without chemotherapy — correlates with extended survival in one of the most treatment-resistant cancers known to medicine supports the broader platform thesis: that immune competence is foundational, and that when you restore it, therapeutic outcomes across disease types can improve.
The Broader Clinical Pipeline
Beyond the approved bladder cancer indication and the programs described above, ImmunityBio is running clinical programs across multiple additional disease areas. Interested patients and providers can search for active ImmunityBio trials on ClinicalTrials.gov. Here's a comprehensive snapshot of the active pipeline as of March 2026:
| Indication | Approach | Stage | Key Data Point |
|---|---|---|---|
| Bladder Cancer (NMIBC CIS) | Anktiva + BCG | Approved (4 Jurisdictions) | 33 countries; 71% complete response rate; 96% 3-yr disease-specific survival (papillary) |
| Bladder Cancer (BCG-Naïve) | Anktiva + BCG | Phase 2/3 | 100% enrollment reached; positive interim analysis; BLA filing targeted Q4 2026 |
| Bladder Cancer (Papillary-Only) | Anktiva + BCG | FDA Review | Response submitted to FDA regarding additional data; awaiting Agency review |
| Lung Cancer (NSCLC) | Anktiva + checkpoint inhibitors | Approved (KSA) | First global approval outside bladder cancer; 14.1-month mOS in CPI-relapsed NSCLC; multi-tumor expansion discussions with SFDA |
| Glioblastoma | Anktiva + CAR-NK (chemo-free) | Phase 2 | 19/23 alive; mOS not reached (historical: 6–9 months); lymphopenia reversed; 0 CRS/ICANS events |
| Non-Hodgkin Lymphoma | CD19 CAR-NK + Anktiva | Phase 2 | 15-month durable complete response in Waldenstrom lymphoma (chemo-free) |
| Indolent Lymphomas | CD19 CAR-NK + Anktiva (ResQ215B) | Phase 2 | Trial launched February 2026; chemotherapy-free design |
| Lynch Syndrome | NANT Cancer Vaccine + Anktiva | Phase 2 (NCI) | First cancer prevention vaccine of its kind; randomized controlled phase initiated |
| Endometrial Cancer | AdHER2DC vaccine + Anktiva | Phase 1/2 | 60-patient enrollment; NCI-partnered; completion expected 2026 |
| Ovarian Cancer | M-CENK + Anktiva + gemcitabine | Phase 2 | Autologous NK cell therapy in platinum-resistant high-grade ovarian cancer |
| Lymphopenia | Anktiva monotherapy | Phase 2 | Treating chemotherapy-induced immune suppression across tumor types |
| Multi-Tumor (CPI-Relapsed) | Anktiva + checkpoint inhibitors | Phase 2 (Basket) | QUILT-3.055: Activity across NSCLC, urothelial, head & neck, melanoma, renal, gastric, cervical |
| Sepsis | Anktiva | Clinical Program | Included in 3-year global strategy for BioShield platform |
Addressing the Global BCG Shortage
A significant but often overlooked component of ImmunityBio's strategy involves addressing the global shortage of BCG — the tuberculosis vaccine that is also a cornerstone of bladder cancer treatment. BCG supply constraints have affected bladder cancer patients worldwide, with more than half of U.S. urologists reporting an inability to treat patients due to lack of access to Tice BCG in a recent survey.
ImmunityBio has an exclusive global licensing and supply arrangement with the Serum Institute of India — the world's largest vaccine manufacturer by number of doses produced — for a recombinant BCG (rBCG). The Serum Institute's manufacturing facility in Pune has been inspected and certified by the WHO, EMA, and FDA. In the United States, the FDA has authorized an Expanded Access Program for rBCG, which is now active at approximately 100 clinical sites with over 500 patients enrolled and several thousand doses administered. Phase 1/2 clinical trials conducted in Europe demonstrated that rBCG showed potent immunogenicity with an improved safety profile compared to standard BCG formulations.
During the February 2026 SFDA engagement, Saudi regulators encouraged ImmunityBio to submit a regulatory package for rBCG to address BCG access in the Kingdom, with the submission expected within weeks. A U.S. FDA meeting for rBCG is also scheduled for March 2026. If rBCG achieves broad regulatory clearance, it would not only address a critical supply gap but also provide a natural commercial synergy with Anktiva (which is used in combination with BCG), potentially positioning ImmunityBio to supply both components of the treatment regimen.
The Regulatory Landscape Is Shifting
Part of what makes this moment in ImmunityBio's trajectory interesting from a healthcare industry perspective is the broader regulatory context. FDA Commissioner Dr. Robert Makary has published guidance in the New England Journal of Medicine introducing the concept of a "plausible mechanism of action" pathway — suggesting that when a therapy's pharmacological effect aligns with established biological mechanisms, smaller, more targeted studies could support licensure rather than requiring separate large-scale trials for each individual indication.
As Dr. Soon-Shiong noted during the Q4 2025 earnings call, Dr. Makary's guidance specifically addresses scenarios where a single disease has many genetic mutations with the same functional implications — where requiring separate trials for each mutation would be impractical, but the biological plausibility of the mechanism of action provides a rational basis for broader authorization.
For a platform like ImmunityBio's — where the core mechanism (restoring immune competence via IL-15 stimulation) is consistent across indications, and the variable is the specific target antigen or combination partner — this regulatory evolution could significantly accelerate the path from lab to patient for new applications. The Saudi FDA's willingness to initiate discussions about expanding Anktiva plus checkpoint inhibitor combinations across multiple tumor types beyond NSCLC may be an early indicator of how this regulatory philosophy plays out internationally.
Cancer 2035: A Seat at the Table
On February 23–24, 2026, Dr. Patrick Soon-Shiong took the stage at "Cancer 2035: A Roadmap for the Future" — a landmark summit co-hosted by the Milken Institute and the Richard Nixon Foundation in Washington, D.C., coinciding with the 55th anniversary of the National Cancer Act. The event convened what may be the most distinguished assembly of cancer research and policy leaders in recent memory, including Nobel Laureate Jim Allison (the pioneer of checkpoint inhibitor therapy), three former NIH Directors (Monica Bertagnolli, Francis Collins, and Elias Zerhouni), CAR-T pioneer Carl June, the CEO of ASCO, and leaders from MD Anderson, Memorial Sloan Kettering, the Parker Institute, and Merck's oncology division.
Dr. Soon-Shiong's inclusion alongside this group reflects the growing recognition of ImmunityBio's approach within the broader oncology research community. The summit's agenda — focusing on prevention as the next frontier, redesigning clinical trial infrastructure, mobilizing public-private partnerships, and using technology as a force multiplier — aligns closely with the strategic direction ImmunityBio has been pursuing.
Why This Matters for Healthcare Professionals
Regardless of where ImmunityBio's stock price goes, the underlying science represents a meaningful shift in how we think about cancer treatment. The idea of restoring immune competence as a foundational layer — and then deploying targeted tools on top of that restored immune system — challenges the chemotherapy-first paradigm that has dominated oncology for decades.
For healthcare providers, this is worth watching for several reasons. The potential expansion of immunotherapy options for patients who have exhausted standard treatments — particularly in glioblastoma, where the chemo-free approach is showing early survival signals well beyond historical benchmarks. The emergence of true cancer prevention vaccines for high-risk populations like those with Lynch Syndrome. The growing global accessibility of these treatments, with 33-country authorization enabling more patient referral options. And the development of solutions to the global BCG shortage that has left bladder cancer patients without access to a foundational treatment.
For healthcare practices, staying informed about these developments ensures better patient conversations, more accurate treatment landscape discussions, and the ability to refer patients to clinical trials when appropriate. The expanded access programs — both for Anktiva and rBCG — represent concrete options that providers can discuss with eligible patients today.
What to Watch Next
Several near-term catalysts will help determine whether ImmunityBio's platform thesis translates into sustained clinical and commercial success:
BCG-Naïve BLA Filing (Q4 2026): With enrollment complete and a positive interim analysis, the biologics license application for the BCG-naïve indication would significantly expand the addressable bladder cancer patient population if approved.
European & Saudi Arabian Commercial Launches: Product shipments to Saudi Arabia are expected within 60 days. The Accord Healthcare partnership will begin deploying sales teams across 30 European countries. These launches will test whether the strong U.S. adoption (750% unit sales growth) translates internationally.
rBCG Regulatory Progress: The SFDA submission is expected within weeks. The U.S. FDA meeting is scheduled for March 2026. Broad approval of rBCG would address a critical global supply gap and create commercial synergy with Anktiva.
Glioblastoma Randomized Trials: Randomized controlled trials for both first-line and second-line GBM patients are in development. These will provide the controlled evidence needed to validate the remarkable early signals from QUILT-3.078.
Multi-Tumor CPI Expansion: The SFDA discussions about expanding Anktiva plus checkpoint inhibitor combinations into urothelial, head and neck, melanoma, renal, gastric, and cervical cancers could open substantial new markets if additional approvals are granted. U.S. FDA discussions regarding an accelerated approval pathway for NSCLC are also planned for 2026.
Cancer Vaccine Readouts: The Lynch Syndrome prevention trial and the endometrial cancer vaccine study are both expected to produce data in 2026, which could validate the cancer vaccine layer of the platform.
The Financial Context
Any honest assessment of ImmunityBio must also address the financial realities. The company reported a net loss of $351 million in 2025, compared to $414 million in 2024 — an improvement, but still substantial. Research and development expenses were $219 million, driven by accelerating clinical trial programs and manufacturing capacity expansion. SG&A expenses decreased by $19 million year-over-year, reflecting the internalization of commercial teams. The company ended 2025 with $243 million in cash and marketable securities.
The path to profitability remains a future milestone. Biotech companies at this stage of commercial and clinical expansion routinely operate at a loss as they invest in the programs and infrastructure needed to reach scale. The 700% revenue growth and 20% quarter-over-quarter acceleration in Q4 provide evidence of commercial traction, but execution risk is real — particularly as the company navigates simultaneous launches across three geographic regions while funding a multi-indication clinical pipeline.
That said, what ImmunityBio has accomplished in under two years from initial FDA approval — building a 33-country regulatory footprint, generating $113 million in product revenue, producing clinical data across five distinct cancer types plus cancer vaccines, securing major commercial partnerships, addressing the global BCG shortage, and earning a seat alongside Nobel Laureates at the most prominent cancer research summit of the year — is objectively remarkable. Whether this ultimately becomes a generational healthcare company or faces the headwinds common to biotech scaling, the science and its implications for patient care deserve our industry's attention.
For more information on ImmunityBio's platform, clinical trials, and latest news, visit immunitybio.com.
Sources & Further Reading
- ImmunityBio FY 2025 Financial & Operational Highlights (Feb 23, 2026)
- Cancer 2035: A Roadmap for the Future Summit (Feb 23, 2026)
- Saudi Arabia Partnership — Biopharma & Cigalah (Feb 20, 2026)
- EU Distribution Partnership — Accord Healthcare (Feb 19, 2026)
- European Commission Authorization (Feb 18, 2026)
- Saudi FDA Regulatory Engagement & rBCG (Feb 17, 2026)
- Phase 2 CAR-NK Trial in Indolent Lymphomas (Feb 2, 2026)
- Glioblastoma QUILT-3.078 Phase 2 Updated Results (Jan 23, 2026)
- BCG-Naïve Trial Enrollment & Interim Analysis (Jan 16, 2026)
- Waldenstrom Lymphoma CAR-NK Complete Response (Jan 16, 2026)
- Saudi FDA Lung Cancer Approval (Jan 14, 2026)
- Saudi FDA Bladder Cancer Approval (Jan 14, 2026)
- Anktiva + Checkpoint Inhibitors NSCLC Results (Jan 13, 2026)
- 96% Survival at 3 Years — Journal of Urology (Dec 16, 2025)
- Lynch Syndrome Cancer Vaccine Trial Update
- ImmunityBio News & Events